Arrowhead Research Corporation - ARWR STOCK NEWS

Arrowhead Pharmaceuticals (ARWR) reported its fiscal second-quarter financials for the period ending March 31, 2021. The company achieved a revenue of $32.8 million, up from $23.5 million in the previous year, resulting in a net loss of $26.8 million compared to $19.8 million in the same quarter last year. Operating expenses increased to $61 million, driven by research and development costs. Significant clinical updates include positive interim results for the ARO-AAT therapy and submissions for INDs for ARO-ANG3 and ARO-APOC3 treatments.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has announced promising interim results from its AROAAT2002 Phase 2 clinical study of ARO-AAT, an RNAi therapeutic for alpha-1 antitrypsin deficiency (AATD). After 48 weeks, 80% of patients showed significant improvement in fibrosis, while total intra-hepatic Z-AAT decreased by 77-97%. Following 24 weeks of treatment, two patients also improved. Arrowhead plans to share further data at a medical congress and is pursuing accelerated approval pathways. The collaboration with Takeda continues to deliver encouraging outcomes.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) will host a webcast and conference call on May 4, 2021, at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March 31, 2021. Investors can join via the company's website or by dialing in. A replay will be available after the call for 90 days. Arrowhead is focused on developing RNAi-based therapeutics aimed at treating intractable diseases through gene silencing.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced ARO-DUX4, its first muscle-targeted investigational RNAi therapeutic candidate, aimed at treating facioscapulohumeral muscular dystrophy (FSHD). ARO-DUX4 targets the DUX4 gene, a known cause of muscle degeneration in FSHD. Preclinical data, to be presented at the 28th Annual FSHD Society International Research Congress, indicates ARO-DUX4 can reduce DUX4 expression by over 70%. Arrowhead plans to file for regulatory clearance in Q3 2021 for clinical studies, enhancing its pipeline beyond liver-targeted therapies.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced the submission of an Investigational New Drug Application (IND) for ARO-APOC3, aimed at treating hypertriglyceridemia. Initial studies showed up to a 92% reduction in triglycerides after two doses. Pending FDA review, the company plans to launch Phase 2b and Phase 3 clinical trials targeting severe hypertriglyceridemia and mixed dyslipidemia. These advancements underscore the potential of ARO-APOC3 as a new treatment for patients experiencing severe triglyceride elevation.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported its fiscal first quarter results for the period ended December 31, 2020. The company generated $21.3 million in revenue, down from $29.5 million in the same quarter of 2019. Operating expenses increased to $45.4 million, leading to a net loss of $20.7 million or $0.20 per share, compared to a loss of $2.7 million or $0.03 per share in the previous year. The firm is advancing its clinical pipeline with ongoing trials and collaborations, including a significant agreement with Takeda.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has submitted an Investigational New Drug Application to the FDA for a Phase 2b study of ARO-ANG3, targeting mixed dyslipidemia. The trial aims to evaluate the safety and efficacy of the RNA interference therapeutic, focusing on reducing triglycerides and LDL cholesterol. The upcoming AROANG3-2001 study will enroll 180 participants to establish an effective dosing regimen. CMO Javier San Martin emphasized the need for new therapies in cardiovascular care, highlighting promising preliminary clinical data.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced a webcast and conference call scheduled for February 4, 2021, at 4:30 p.m. EST to discuss its financial results for the fiscal first quarter ending December 31, 2020. Investors can access the live audio webcast on the Company's website. A replay will be available for 90 days post-call. Arrowhead specializes in developing RNA interference-based therapeutics targeting intractable diseases through innovative gene silencing techniques.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced inducement grants for 27 new employees, approved on December 4, 2020. The grants include options to purchase 145,000 shares at a strike price of $65.29 and the potential for 96,000 restricted stock units (RSUs). These grants are outside the stockholder-approved equity incentive plans and will vest over four years. Arrowhead focuses on RNA interference therapies targeting intractable diseases, leveraging gene silencing to effectively treat conditions.